Werfen Receives CE Mark for Aptiva® Antiphospholipid Syndrome Reagents

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Werfen-CE-mark-Aptiva

More Like This

Fujirebio Submits FDA Regulatory Filing for Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease

Roche launches three new Factor Xa inhibitor coagulation tests to meet growing patient need

AliveDx Receives IVDR-CE Mark for Multiplexed Assay to Accurately Detect Celiac Disease (CD) on the MosaiQ® System

Fujirebio Launches the Fully Automated Lumipulse® G GFAP Assay for Research Use Only and Further Strengthens its Neuro Test Menu

AliveDx receives three IVDR CE marks for its Multiplexed Autoimmune Diagnostics Solution

Beckman Coulter and Fujirebio Expand Partnership to Develop Patient-friendly, Blood-based Neurodegenerative Disease Diagnostics

Fujirebio Expands Its Alzheimer’s Disease Test Menu With the Much Awaited and Fully Automated Lumipulse® G pTau 217 Plasma Assay for Research Use Only (RUO)

Fujirebio and Agappe Enter into an Agreement on Business Collaboration in the Field of CLIA Based Immunoassay